At the 2024 Academy Awards, Eli Lilly, the manufacturer of blockbuster weight loss drugs including Mounjaro and Zepbound, criticized people for taking GLP-1s without an obesity diagnosis. In 2025, the pharma giant is changing tack with an attack on its non-FDA-approved rivals. “Healthy Skepticism,” from Wieden+Kennedy, will debut at the 97th Academy Awards on Sunday,…At the 2024 Academy Awards, Eli Lilly, the manufacturer of blockbuster weight loss drugs including Mounjaro and Zepbound, criticized people for taking GLP-1s without an obesity diagnosis. In 2025, the pharma giant is changing tack with an attack on its non-FDA-approved rivals. “Healthy Skepticism,” from Wieden+Kennedy, will debut at the 97th Academy Awards on Sunday,… Read More
